Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Recruiting 1

Sponsor Class

OTHER 18OTHER_GOV 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Pancreatic Neoplasms 1

Interventions

pembrolizumab 302Carboplatin 228Cisplatin 157Gemcitabine 155Paclitaxel 154Pemetrexed 122Bevacizumab 121Docetaxel 105Oxaliplatin 84durvalumab 82Nivolumab 81Fluorouracil 81Dexamethasone 79Cyclophosphamide 78atezolizumab 77130-nm albumin-bound paclitaxel 73Fulvestrant 71Capecitabine 69Injections 65Leucovorin 64Cetuximab 63Rituximab 56Lenalidomide 52fludarabine 51venetoclax 46Prednisone 45Irinotecan 44enzalutamide 41Letrozole 41tislelizumab 38

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × camrelizumab × 90 days × Clear all
NCT06361888 2026-05-28

A Phase II/III Trial to Evaluate the Efficacy and Safety of Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine in Metastatic Pancreatic Cancer

Hutchmed

Phase 2/3 Recruiting
502 enrolled
Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡